Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» XNPT's 30-Y Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Traded in other countries:LMW.Germany,
Headquarter Location:USA
XenoPort Inc is a biopharmaceutical company. It is engaged in developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders.

XenoPort Inc is a Delaware corporation was incorporated on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological and other disorders. Its product candidates are prodrugs that are created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and metabolism of the parent drug. Its marketed product is approved in the United States, where it is known as Horizant Extended-Release Tablets, and in Japan, where it is known as Regnite Extended-Release Tablets. Horizant has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. Restless legs syndrome, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. Regnite has been approved by the Japanese Ministry of Health, Labor and Welfare, or MHLW, as a treatment for patients with moderate-to-severe RLS. It is also engaged with third parties for the development of arbaclofen placarbil, or AP, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson's disease. The Company faces competition from manufacturers of generic drugs. The Company is subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as governmental authorities in those foreign countries in which it may commercialize its products.



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $48.22
EPS (TTM) $ -1.20
Short Percentage of Float11.35%
52-Week Range $3.35 - 7.86
Shares Outstanding (Mil)63.53

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 115 90
EPS ($) -0.06 -0.77
EPS without NRI ($) -0.06 -0.77
EPS Growth Rate
(Future 3Y To 5Y Estimate)
Dividends per Share ($)
» More Articles for XNPT


Articles On GuruFocus.com
XenoPort Inc. Reports Operating Results (10-Q) Nov 09 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2010 
XenoPort Inc. Reports Operating Results (10-Q) May 10 2010 
Xenoport - A Shaking Ham Hock Feb 07 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2009 
Weekly Top Insider Buys: Alcoa Inc., ABM Industries Inc., Valhi Inc., XenoPort Inc., and Methode Ele Jul 11 2009 
XenoPort Inc. Reports Operating Results (10-Q) May 07 2009 
Weekly Top Insider Buys: Sovereign Bancorp Inc., Jefferies Group Inc., XenoPort Inc., Sandridge Ener May 24 2008 

More From Other Websites
Arbor Pharmaceuticals Completes Successful Tender Offer for Shares of XenoPort Jul 05 2016
Arbor Pharmaceuticals, LLC -- Moody's Assigns B1 CFR to Arbor Pharmaceuticals; Stable Outlook Jun 21 2016
Surging Earnings Estimates Signal Good News for Xenoport (XNPT) Jun 06 2016
Why Xenoport, Inc. Stock Jumped 61.1% in May Jun 04 2016
SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of... May 27 2016
What Investors Missed in the Stock Market This Week May 27 2016
The Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie May 26 2016
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well May 25 2016
Xenoport Surges on Takeover Bid and Outperforms the Market May 24 2016
ETF’s with exposure to XenoPort, Inc. : May 24, 2016 May 24 2016
Xenoport to be Acquired by Arbor Pharmaceuticals; Stock Up May 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat